论文部分内容阅读
Aim: To investigate the mechanisms of interleukin-1 receptor antagonist (IL-1ra)in the treatment of adjuvant arthritis (AA). Methods: AA was induced in rats by treatment with Freund’s complete adjuvant (FCA). Rats were given an intracutaneous injection of IL-1ra (2.5, 10, 40 mg/kg, 3 times per day) from d 14 to d 21 after immunization. Synoviocyte proliferation and the activity of IL-1 were determined by using MTT assay. Tumor necrosis factor alpha (TNF-α) and prostaglandin E2(PGE2) concentrations were measured by radioimmunoassay. The ultrastructure of synoviocytes was observed by using a transmission electron microscope.Phosphorylation of c-Jun N-terminal kinase (JNK), extracellular regulating kinase (ERK) and p38 kinase were detected by West blot analysis. Results: IL-1ra (10and 40 mg/kg, ic, d 14-21) modulated the secondary inflammatory reaction (P＜0.01), ultrastructure of synoviocytes and mitogen-activated protein kinase (MAPK) phosphorylation in AA rats. The administration of IL-1ra (10 and 40mg/kg, ic, d 14-21) in AA rats significantly decreased the production of IL-1, PGE2and TNF-α by macrophage-like synoviocytes (MLS) (P＜0.01). IL-1 ra (2.5 mg/kg)also decreased the production of PGE2 (P＜0.01) and TNF-α(P＜0.05) by MLS in AA rats. The increased phosphorylation of MAPK and cell proliferation in fibroblast-like synoviocytes (FLS) stimulated by supatants of MLS in AA rats was also inhibited by IL-1ra (10 and 40 mg/kg, ic, d 14-21). Conclusion: IL-1ra has anti-inflammatory effects because it modulates the ultrastructure of synoviocytes,decreases the production of pro-inflammatory mediators by MLS, and inhibits the phosphorylation of MAPK in FLS.